Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
The therapy uses the AAV-SLB101 capsid and a specialized cargo (nNOS binding domain) to potentially boost dystrophin expression compared to earlier-generation treatments.Wedbush initiated coverage on Solid Biosciences, Inc. (NASDAQ:SLDB), a gene therapy company focused on treating Duchenne muscular dystrophy (DMD).
Wedbush對Solid Biosciences, Inc.（納斯達克：SLDB）啓動了覆蓋，此公司是一家專注於治療杜氏肌營養不良症（DMD）的基因治療公司。
DMD is a genetic disease that causes progressive muscle weakness and wasting.
DMD是一種遺傳性疾病，導致肌肉逐漸無力和萎縮。
SGT-003 is the leading program in Solid Biosciences' pipeline, with plans to advance additional projects toward clinical trials in 2025.
SGt-003是Solid Biosciences管線中的領先項目，計劃在2025年推進其他項目進入臨床試驗。
The therapy uses the AAV-SLB101 capsid and a specialized cargo (nNOS binding domain) to potentially boost dystrophin expression compared to earlier-generation treatments.
該療法使用AAV-SLB101衣殼和一種專門的載體（nNOS結合域），有可能增強肌萎縮蛋白的表達，相比於早期世代的治療。
While first-generation gene therapy for Duchenne muscular dystrophy (DMD) opens new treatment possibilities, there is still room for improvement. The analyst writes that Solid Biosciences' innovative approach and novel capsid technology could enhance microdystrophin delivery.
雖然第一代基因治療爲杜氏肌營養不良症（DMD）開闢了新的治療可能性，但仍有改進的空間。這位分析師認爲，Solid Biosciences的創新方法和新型衣殼技術可以增強微型肌萎縮蛋白的遞送。
Although the company's pipeline offers multiple opportunities, current projections focus only on SGT-003 for DMD.
儘管公司的管線提供了多個機會，但當前的預測僅集中在SGt-003用於DMD。
The most significant near-term milestone for Solid Biosciences is the initial Phase 1/2 INSPIRE DUCHENNE trial results, expected in the first quarter of 2025.
Solid Biosciences近期最重要的里程碑是初步的1/2期INSPIRE DUCHENNE試驗結果，預計在2025年第一季度發佈。
Approving Sarepta Therapeutics Inc's (NASDAQ:SRPT) Elevidys was a key milestone in treating Duchenne muscular dystrophy (DMD), but it's only the beginning. Newer treatments with better and more reliable results are still needed.
批准Sarepta Therapeutics Inc（納斯達克：SRPT） 的Elevidys是治療杜氏肌營養不良症（DMD）的一個關鍵里程碑，但這僅僅是開始。仍然需要更好且更可靠的治療方法。
Wedbush analyst writes, "We see Solid Biosciences in a "solid" position to deliver a next-gen therapeutic option."
Wedbush的分析師寫道："我們認爲Solid Biosciences處於一個'穩固'的位置，可以提供下一代治療選擇。"
Wedbush writes that Solid Biosciences' stock trade at around $5 each, with about $4 per share in cash providing some downside protection.
Wedbush寫道，Solid Biosciences的股票交易價格約爲每股5美元，現金約爲每股4美元，提供了一定的下行保護。
Assuming Solid Biosciences' SGT-003 program follows a timeline similar to Sarepta's Elevidys, even a one-year delay would lower the price target to $11 per share (current price target of $16)—still above the current trading price.
假設Solid Biosciences的SGt-003項目遵循與Sarepta的Elevidys類似的時間表，即使延遲一年，目標價格也會降低到每股11美元（目前的目標價格爲每股16美元）——仍然高於當前交易價格。
With other programs yet to be included in the valuation, the analyst sees strong potential and initiates with an Outperform rating.
由於其他項目尚未納入估值，分析師看到強勁的潛力，並將其評級初始定爲跑贏大盤。
Solid Biosciences ended the third quarter of 2024 with approximately $171.1 million in cash, cash equivalents, and available-for-sale securities, with an anticipated cash runway into 2026.
Solid Biosciences在2024年第三季度結束時，擁有約17110萬美元的現金、現金等價物和可供出售證券，預計現金使用可持續到2026年。
Price Action: SLDB stock is up 3.21% at $4.83 at the last check on Friday.
價格動態：截至上週五最後檢查，SLDb股票上漲3.21%，報每股4.83美元。
- Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
- 吉利德推出年度新型HIV注射劑，爲減少預防給藥頻率提供希望
譯文內容由第三人軟體翻譯。
